1
|
Olennikov DN, Kashchenko NI. Gentianopsis metabolites and bioactivity: HPLC-PDA-ESI-tQ-MS/MS profiles, HPLC-UV quantification of Gentianopsis komarovii and Gentianopsis stricta, and choleretic potential. Nat Prod Res 2024; 38:158-163. [PMID: 35921543 DOI: 10.1080/14786419.2022.2107640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Accepted: 07/26/2022] [Indexed: 11/09/2022]
Abstract
Gentianopsis is a small gentianaceous genus with a known ethnopharmacological focus as hepatoprotectors containing two underestimated species that are scientifically unexplored: Gentianopsis komarovii (Grossh.) Toyok., which is typical of the Far East, and Gentianopsis stricta (Klotzsch) Ikonn., which is grown in Central Asia. Application of the HPLC-PDA-ESI-tQ-MS/MS technique led to the identification of 28 compounds, such as iridoid glycosides, flavones and xanthones, with loganic acid, sweroside, loganin, secologanin, isoorientin-7-O-glucoside, luteolin-7-O-gentiobioside, chrysoeriol-7-O-glucoside and acacetin-7-O-glucoside being found in the genus for the first time. The extracts of G. komarovii and G. stricta demonstrated choleretic potential, strengthening the bile flow and the total content of bile acids, bilirubin and cholesterol in the bile. The most pronounced effects were observed for luteolin-7-O-glucoside and gentiabavaroside (gentiacaulein-1-O-primveroside), establishing them as the principle choleretics of both herbs. Based on the results, G. komarovii, G. stricta and some phenolic metabolites are prospective new choleretic drugs.
Collapse
Affiliation(s)
- Daniil N Olennikov
- Institute of General and Experimental Biology, Laboratory of Medical and Biological Research, Ulan-Ude, Russia
| | - Nina I Kashchenko
- Institute of General and Experimental Biology, Laboratory of Medical and Biological Research, Ulan-Ude, Russia
| |
Collapse
|
2
|
Huang PQ, Kang KW, Huang DY, Zhao CL, Zheng H, Luo YX, Wen Y, Zou MF, Li DL, Wu RH, Tian YC, Tian Y, Zhang WH, Jin JW, Yin S, Gan LS. Lignan glucosides from Gentiana macrophylla with potential anti-arthritis and hepatoprotective activities. PHYTOCHEMISTRY 2024; 217:113920. [PMID: 37951561 DOI: 10.1016/j.phytochem.2023.113920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/14/2023] [Revised: 11/04/2023] [Accepted: 11/07/2023] [Indexed: 11/14/2023]
Abstract
Ten lignans, including six previously undescribed phenolic ester glycosyl lignans (1-6), were isolated from a well-known traditional Chinese medicine, Qin-Jiao, which is the dry root of Gentiana macrophylla Pall. (Gentianaceae). Their structures were determined by spectroscopic and chemical methods, especially 2D NMR techniques. Quantum chemical calculations of theoretical ECD spectra allowed the determination of their absolute configurations. Refer to its traditional applications for the treatment of rheumatic arthralgia and hepatopathy, these compounds were evaluated on a TNF-α induced MH7A human synoviocyte inflammation model and a D-GalN induced AML12 hepatocyte injury model. Compounds 1, 2, 5, and 6 significantly reduced the release of proinflammatory cytokine IL-1β in MH7A cells at 15 μM and they also could strongly protect AML12 cells against D-GalN injury at 30 μM. Flow cytometry and Western blot analysis showed that compound 5 ameliorated D-GalN induced AML12 cell apoptosis by upregulating the expression of anti-apoptotic Bcl-2 protein and down-regulating the expression of pro-apoptotic Bax protein.
Collapse
Affiliation(s)
- Pei-Qi Huang
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen, 529020, PR China
| | - Kai-Wen Kang
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen, 529020, PR China
| | - Dan-Yu Huang
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen, 529020, PR China
| | - Chun-Lin Zhao
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen, 529020, PR China
| | - Hao Zheng
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen, 529020, PR China
| | - Yong-Xin Luo
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen, 529020, PR China
| | - Yan Wen
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen, 529020, PR China
| | - Ming-Feng Zou
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China
| | - Dong-Li Li
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen, 529020, PR China
| | - Ri-Hui Wu
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen, 529020, PR China
| | - Yun-Cai Tian
- Shanghai ZZZC Tech. Ltd, 400 Zhuanghangbei Rd, Shanghai, 201415, PR China
| | - Yong Tian
- Shanghai ZZZC Tech. Ltd, 400 Zhuanghangbei Rd, Shanghai, 201415, PR China
| | - Wen-Huan Zhang
- Shanghai ZZZC Tech. Ltd, 400 Zhuanghangbei Rd, Shanghai, 201415, PR China
| | - Jing-Wei Jin
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen, 529020, PR China.
| | - Sheng Yin
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China.
| | - Li-She Gan
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen, 529020, PR China; College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
| |
Collapse
|
3
|
Huang PQ, Luo YX, Zhang YJ, Li ZX, Wen Y, Zhang K, Li DL, Jin JW, Wu RH, Gan LS. Terpenoid Glucosides from Gentiana macrophylla That Attenuate TNF-α Induced Pulmonary Inflammation in A549 Cells. Molecules 2023; 28:6613. [PMID: 37764389 PMCID: PMC10535684 DOI: 10.3390/molecules28186613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Revised: 07/28/2023] [Accepted: 08/10/2023] [Indexed: 09/29/2023] Open
Abstract
Four previously undescribed terpenoid glucosides, including one sesquiterpenoid di-glucoside (1), two new iridoid glucosides (2, 3), and a new triterpenoid tri-glucoside (4), were isolated from a 70% ethanol extract of the root of Gentiana macrophylla (Gentianaceae), along with eight known terpenoids. Their structures were determined by spectroscopic techniques, including 1D, 2D NMR, and HRMS (ESI), as well as chemical methods. The absolute configuration of compound 1 was determined by quantum chemical calculation of its theoretical electronic circular dichroism (ECD) spectrum. The sugar moieties of all the new compounds were confirmed to be D-glucose by GC analysis after acid hydrolysis and acetylation. Anti-pulmonary inflammation activity of the iridoids were evaluated on a TNF-α induced inflammation model in A549 cells. Compound 2 could significantly alleviate the release of proinflammatory cytokines IL-1β and IL-8 and increase the expression of anti-inflammatory cytokine IL-10.
Collapse
Affiliation(s)
- Pei-Qi Huang
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen 529020, China; (P.-Q.H.); (Y.-X.L.); (Y.-J.Z.); (Z.-X.L.); (Y.W.); (K.Z.); (D.-L.L.); (J.-W.J.)
| | - Yong-Xin Luo
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen 529020, China; (P.-Q.H.); (Y.-X.L.); (Y.-J.Z.); (Z.-X.L.); (Y.W.); (K.Z.); (D.-L.L.); (J.-W.J.)
| | - Yu-Jia Zhang
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen 529020, China; (P.-Q.H.); (Y.-X.L.); (Y.-J.Z.); (Z.-X.L.); (Y.W.); (K.Z.); (D.-L.L.); (J.-W.J.)
| | - Zhi-Xuan Li
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen 529020, China; (P.-Q.H.); (Y.-X.L.); (Y.-J.Z.); (Z.-X.L.); (Y.W.); (K.Z.); (D.-L.L.); (J.-W.J.)
| | - Yan Wen
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen 529020, China; (P.-Q.H.); (Y.-X.L.); (Y.-J.Z.); (Z.-X.L.); (Y.W.); (K.Z.); (D.-L.L.); (J.-W.J.)
| | - Kun Zhang
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen 529020, China; (P.-Q.H.); (Y.-X.L.); (Y.-J.Z.); (Z.-X.L.); (Y.W.); (K.Z.); (D.-L.L.); (J.-W.J.)
| | - Dong-Li Li
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen 529020, China; (P.-Q.H.); (Y.-X.L.); (Y.-J.Z.); (Z.-X.L.); (Y.W.); (K.Z.); (D.-L.L.); (J.-W.J.)
| | - Jing-Wei Jin
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen 529020, China; (P.-Q.H.); (Y.-X.L.); (Y.-J.Z.); (Z.-X.L.); (Y.W.); (K.Z.); (D.-L.L.); (J.-W.J.)
| | - Ri-Hui Wu
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen 529020, China; (P.-Q.H.); (Y.-X.L.); (Y.-J.Z.); (Z.-X.L.); (Y.W.); (K.Z.); (D.-L.L.); (J.-W.J.)
| | - Li-She Gan
- School of Biotechnology and Health Sciences, International Healthcare Innovation Institute, Wuyi University, Jiangmen 529020, China; (P.-Q.H.); (Y.-X.L.); (Y.-J.Z.); (Z.-X.L.); (Y.W.); (K.Z.); (D.-L.L.); (J.-W.J.)
- College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058, China
| |
Collapse
|
4
|
Liu CF. Recent Advances on Natural Aryl- C-glycoside Scaffolds: Structure, Bioactivities, and Synthesis-A Comprehensive Review. Molecules 2022; 27:7439. [PMID: 36364266 PMCID: PMC9654268 DOI: 10.3390/molecules27217439] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2022] [Revised: 10/28/2022] [Accepted: 10/31/2022] [Indexed: 09/23/2023] Open
Abstract
Aryl-C-glycosides, of both synthetic and natural origin, are of great significance in medicinal chemistry owing to their unique structures and stability towards enzymatic and chemical hydrolysis as compared to O-glycosides. They are well-known antibiotics and potent enzyme inhibitors and possess a wide range of biological activities such as anticancer, antioxidant, antiviral, hypoglycemic effects, and so on. Currently, a number of aryl-C-glycoside drugs are on sale for the treatment of diabetes and related complications. This review summarizes the findings on aryl-C-glycoside scaffolds over the past 20 years, concerning new structures (over 200 molecules), their bioactivities-including anticancer, anti-inflammatory, antioxidant, antivirus, glycation inhibitory activities and other pharmacological effects-as well as their synthesis.
Collapse
Affiliation(s)
- Chen-Fu Liu
- School of Pharmaceutical Sciences, Gannan Medical University, Ganzhou 341000, China
| |
Collapse
|
5
|
Zhang YQ, Zhang M, Wang ZL, Qiao X, Ye M. Advances in plant-derived C-glycosides: Phytochemistry, bioactivities, and biotechnological production. Biotechnol Adv 2022; 60:108030. [PMID: 36031083 DOI: 10.1016/j.biotechadv.2022.108030] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Revised: 08/01/2022] [Accepted: 08/22/2022] [Indexed: 02/06/2023]
Abstract
C-glycosides represent a large group of natural products with a C-C bond between the aglycone and the sugar moiety. They exhibit great structural diversity, wide natural distribution, and significant biological activities. By the end of 2021, at least 754 C-glycosides and their derivatives have been isolated and characterized from plants. Thus far, 66 functional C-glycosyltransferases (CGTs) have been discovered from plants, and provide green and efficient approaches to synthesize C-glycosides. Herein, advances in plant-derived C-glycosides are comprehensively summarized from aspects of structural diversity and identification, bioactivities, and biotechnological production. New strategies to discover novel C-glycosides and CGTs, as well as the applications of biotechnological methods to produce C-glycosides in the future are also discussed.
Collapse
Affiliation(s)
- Ya-Qun Zhang
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, 38 Xueyuan Road, Beijing 100191, China
| | - Meng Zhang
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, 38 Xueyuan Road, Beijing 100191, China
| | - Zi-Long Wang
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, 38 Xueyuan Road, Beijing 100191, China
| | - Xue Qiao
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, 38 Xueyuan Road, Beijing 100191, China; Peking University-Yunnan Baiyao International Medical Research Center, 38 Xueyuan Road, Beijing 100191, China.
| | - Min Ye
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, 38 Xueyuan Road, Beijing 100191, China; Peking University-Yunnan Baiyao International Medical Research Center, 38 Xueyuan Road, Beijing 100191, China; Key Laboratory of Molecular Cardiovascular Sciences of Ministry of Education, Peking University, 38 Xueyuan Road, Beijing 100191, China.
| |
Collapse
|
6
|
Olennikov DN, Chemposov VV, Chirikova NK. Metabolites of Prickly Rose: Chemodiversity and Digestive-Enzyme-Inhibiting Potential of Rosa acicularis and the Main Ellagitannin Rugosin D. PLANTS (BASEL, SWITZERLAND) 2021; 10:2525. [PMID: 34834888 PMCID: PMC8622385 DOI: 10.3390/plants10112525] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/04/2021] [Revised: 11/13/2021] [Accepted: 11/18/2021] [Indexed: 05/13/2023]
Abstract
Prickly rose (Rosaacicularis Lindl.) is the most distributed rose species in the Northern Hemisphere, used by indigenous people for various food purposes. The lack of detailed information about the chemical composition of R. acicularis has led us to study the phytochemical composition and metabolic profile of prickly rose extracts using chromatographic techniques. Many groups of phenolic and non-phenolic compounds were quantified in the leaves, flowers, roots and fruits of R. acicularis. Phenolic compounds were the dominant phytochemicals in the aerial parts and roots of R. acicularis. A precise study by high-performance liquid chromatography with photodiode array detection and electrospray ionization triple quadrupole mass spectrometric detection showed the presence of 123 compounds, among which ellagic acid derivatives, ellagitannins, gallotannins, catechins, catechin oligomers, hydroxycinnamates and flavonoid glycosides of kaempferol, quercetin and dihydroquercetin were all identified for the first time. The most abundant phenolic compounds were ellagitannins and flavonoid glycosides, with a maximal content of 70.04 mg/g in leaves and 66.72 mg/g in flowers, respectively, indicating the great ability of R. acicularis organs to accumulate phenolic compounds. By applying a standardized static, simulated gastrointestinal digestion method, we found the inhibitory potential of the leaf extract against digestive α-amylases. A pancreatic α-amylase activity-inhibiting assay coupled with HPLC microfractionation demonstrated high inhibition of enzyme activity by ellagitannin rugosin D, which was later confirmed by a microplate reaction with mammalian α-amylases and the simulated digestion method. This study clearly demonstrates that R. acicularis leaf extract and its main component, ellagitannin rugosin D, strongly inhibit digestive α-amylase, and may be a prospective antidiabetic agent.
Collapse
Affiliation(s)
- Daniil N. Olennikov
- Laboratory of Medical and Biological Research, Institute of General and Experimental Biology, Siberian Division, Russian Academy of Science, 670047 Ulan-Ude, Russia
| | - Vladimir V. Chemposov
- Department of Biology, Institute of Natural Sciences, North-Eastern Federal University, 677027 Yakutsk, Russia; (V.V.C.); (N.K.C.)
| | - Nadezhda K. Chirikova
- Department of Biology, Institute of Natural Sciences, North-Eastern Federal University, 677027 Yakutsk, Russia; (V.V.C.); (N.K.C.)
| |
Collapse
|